Modified staging classification of gallbladder carcinoma on the basis of the 8th edition of the American Joint Commission on Cancer (AJCC) staging system

被引:7
|
作者
Wang, Jie [1 ]
Bo, Xiaobo [1 ]
Shi, Xiao [2 ]
Suo, Tao [1 ]
Xin, Yanlei [1 ]
Nan, Lingxi [1 ]
Wang, Changcheng [1 ]
Ni, Xiaoling [1 ]
Liu, Han [1 ]
Pan, Hongtao [1 ]
Shen, Sheng [1 ]
Li, Min [1 ]
Lu, Pinxiang [3 ]
Zhang, Dexiang [3 ]
Wang, Zhiqin [3 ]
Wang, Yueqi [1 ]
Liu, Houbao [1 ,3 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Head & Neck Surg, Shanghai, Peoples R China
[3] Fudan Univ, Dept Gen Surg, Zhongshan Xuhui Hosp, Shanghai, Peoples R China
来源
EJSO | 2020年 / 46卷 / 04期
基金
中国国家自然科学基金;
关键词
Gallbladder cancer; 8th; AJCC; SEER; Staging system; STATISTICS; RESECTION; SURVIVAL; IMPACT;
D O I
10.1016/j.ejso.2019.10.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The 8th edition of the American Joint Commission on Cancer (AJCC) Staging System for gallbladder cancer (GBC) has been used in clinical practice, but we have found some deficiencies in this edition. Methods: Survival analyses were performed to evaluate the application of various editions of the AJCC staging systems using the Surveillance, Epidemiology, and End Results (SEER) database (N = 9616 patients) and Fudan University Zhongshan Hospital (FUZH) database (N = 327 patients). A modified staging system was proposed based on the 8th edition of the AJCC Staging System. Results: Although all N2 diseases were grouped into stage IVB as M1 in the 8th edition, some patients with N2 diseases could undergo RO resection, and had longer survival than patients with M1 diseases had in both cohorts (p <0.001 in SEER, p = 0.041 in FUZH). Furthermore, in the SEER database, stage IIIA patients aberrantly had poorer survival than stage IIIB patients had (p < 0.001). Therefore, we proposed a modified staging system by rearranging the substages. N2 disease was subdivided and reappraised according to T stage, and the aberrant survival reversal of stage IIIA and stage IIIB disease was also corrected. Through our modification, the C-index of the 8th AJCC Staging System was elevated from 0.596 [95% confidence interval (CI): 0.585-0.607] to 0.623 (95% CI 0.612-0.634) for local disease in the SEER cohort. Similar findings were also observed in the FUZH cohort. Conclusion: Our modified 8th AJCC Staging System is more suitable for GBC and could be adopted for clinical practice. (C) 2019 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:527 / 533
页数:7
相关论文
共 50 条
  • [31] Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of the 8th Edition AJCC Staging System
    Yi, M.
    Hunt, K.
    Bedrosian, I.
    Chavez-MacGregor, M.
    Mittendorf, E. A.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S25 - S26
  • [32] Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification
    Bhindi, Bimal
    Karnes, R. Jeffrey
    Rangel, Laureano J.
    Mason, Ross J.
    Gettman, Matthew T.
    Frank, Igor
    Tollefson, Matthew K.
    Lin, Daniel W.
    Thompson, R. Houston
    Boorjian, Stephen A.
    JOURNAL OF UROLOGY, 2017, 198 (06): : 1287 - 1295
  • [33] The updated AJCC/TNM staging system (8th edition) for oral tongue cancer
    Kim, Kyubo
    Lee, Dong Jin
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S164 - S166
  • [34] Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis
    Kamarajah, Sivesh K.
    Burns, William R.
    Frankel, Timothy L.
    Cho, Clifford S.
    Nathan, Hari
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (07) : 2023 - 2030
  • [35] Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis
    Kim, Yuhree
    Moris, Dimitrios P.
    Zhang, Xu-Feng
    Bagante, Fabio
    Spolverato, Gaya
    Schmidt, Carl
    Dilhoff, Mary
    Pawlik, Timothy M.
    JOURNAL OF SURGICAL ONCOLOGY, 2017, 116 (06) : 643 - 650
  • [36] Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis
    Sivesh K. Kamarajah
    William R. Burns
    Timothy L. Frankel
    Clifford S. Cho
    Hari Nathan
    Annals of Surgical Oncology, 2017, 24 : 2023 - 2030
  • [37] An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma
    Tran, Bryan
    Roshan, David
    Abraham, Earl
    Wang, Laura
    Garibotto, Natalia
    Wykes, James
    Campbell, Peter
    Ebrahimi, Ardalan
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (06): : 2199 - 2206
  • [38] Historical progress of the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual in patients with breast cancer
    Kosaka, Yoshimasa
    Nishimiya, Hiroshi
    Kikuchi, Mariko
    Waraya, Mina
    Katoh, Hiroshi
    Sengoku, Norihiko
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (03) : 719 - 721
  • [39] Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection
    Park, Sujin
    Choi, Sangjoon
    Cho, Yoon Ah
    Sinn, Dong Hyun
    Kim, Jong Man
    Park, Cheol-Keun
    Ha, Sang Yun
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1145 - 1152
  • [40] Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,034 Patients with Curative Resection
    Park, Sujin
    Choi, Sangjoon
    Park, Cheol-Keun
    Sinn, Dong Hyun
    Kim, Jong Man
    Ha, Sang Yun
    MODERN PATHOLOGY, 2019, 32